Toufik Zahaf

7333 Mississauga Rd
Mississauga, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Implementation of the ICH E9 (R1) addendum in vaccine efficacy studies: the hypothetical and principal stratum strategies.

Implementation of the ICH E9 (R1) addendum in vaccine efficacy studies: the hypothetical and principal stratum strategies.

Journal: Journal of biopharmaceutical statistics

Published: October 02, 2025

Dynamic borrowing of historical controls adjusting for covariates in vaccine efficacy clinical trials.

Dynamic borrowing of historical controls adjusting for covariates in vaccine efficacy clinical trials.

Journal: Pharmaceutical statistics

Published: August 23, 2023

Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studies.

Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studies.

Journal: Pharmaceutical statistics

Published: May 03, 2022

Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine.

Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine.

Journal: The Journal of infectious diseases

Published: July 21, 2021

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 31, 2021

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials.

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials.

Journal: Human vaccines & immunotherapeutics

Published: February 19, 2021

Assurance in vaccine efficacy clinical trial design based on immunological responses.

Assurance in vaccine efficacy clinical trial design based on immunological responses.

Journal: Biometrical journal. Biometrische Zeitschrift

Published: January 14, 2021

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials.

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials.

Journal: Human vaccines & immunotherapeutics

Published: April 30, 2020

Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.

Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.

Journal: Rheumatology (Oxford, England)

Published: February 27, 2020

Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials.

Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials.

Journal: Vaccine

Published: July 08, 2019

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.

Journal: Human vaccines & immunotherapeutics

Published: June 20, 2019

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Journal: The New England journal of medicine

Published: September 15, 2016

Showing 1-12 of 20

Last Updated: 09/26/2026